$2,000,000 for patients over 20 years in the United States) make the clinical and economic arguments clear (Habka et al. 2015) Whilst the current focus is on identifying dose-limiting toxicity in patients who have achieved a peak ALT > 1000 U/L, it is not currently clear where cell therapy will sit in the evolution of ALI (Craig et al. 2012). Here, GPT is linked to acute respiratory distress syndrome.